Public participation in Anvisa's regulatory agenda continues until September 15

Those interested in contributing to the construction of the Regulatory Agenda (AR) 2026-2027 of Anvisa have until September 15 to submit their comments.

In this stage of social participation, the National Health Surveillance Agency (Anvisa) receives opinions on the preliminary list of topics and also allows the suggestion of new subjects that are not included. The guidelines were detailed in a promotional video (below).

The current consultation is just a phase of collecting contributions. The final list of topics will be constructed based on these comments and must be approved by the Collegiate Board (Dicol) by the end of this year. Therefore, it is not yet the definitive version of the Regulatory Agenda 2026-2027.

Cannabis not included in the preliminary list

The list does not include direct actions related to resolutions concerning cannabis products in Brazil, such as RDC 327 or RDC 660.

Despite this, Subject No. 3 addresses the revision of Ordinance SVS/MS No. 344/1998, which deals with the control and supervision of substances under special control and plants that can be used for production. This topic is the responsibility of the Controlled Products Management (GPCON).

How to submit contributions

Comments must be submitted via electronic form, available according to Call Notice No. 10, dated 14/8/2025.

The document allows choosing only one macro theme at a time. This means that if a participant wants to comment on different areas — for example, food and medicines — separate forms will need to be filled out.

According to Anvisa, for participation to be effective, contributions must be clear and well-founded, following the guidelines of the participation manual. The more substantiated the contributions, the greater the chances of them being considered by the technical units of the Agency, responsible for the analysis, prioritization, and selection of topics.

History: Cannabis in the 2024-2025 Agenda

In the Regulatory Agenda 2024-2025, topic 2.28, within the category “Medicines,” included the review of the regulation of cannabis products for medicinal purposes (RDC No. 327/2019). The goal was to expand safe access to essential health products and services.

In March 2025, Anvisa advanced the topic by approving a draft Public Consultation to update RDC 327/2019, which defines requirements for the manufacture, import, and commercialization of cannabis-based products in Brazil.

The public consultation was open until June 2 and received 1,476 contributions, including proposals for changes, opinions, and suggestions from society. This information will support adjustments to the final text, which will be submitted for deliberation by Dicol.